While several CVOTs were performed with injectable GLP-1 RAs [46], the recent SOUL trial assessed the use of oral semaglutide, which was associated with a significantly lower risk of MACE than a placebo, without an increase in the incidence of serious adverse events, in patients with T2D and atherosclerotic cardiovascular disease (ASCVD), CKD, or both [71]
Jason Ng, explained the mechanics: Weight loss plateau happens when your bodys energy burn equals energy being added through food. Initially, with weight loss, when you significantly decrease energy intake, the body will get energy needs through other sources such as glycogen
Both berberine and metformin may activate AMPK pathways, reduce hepatic glucose production, and improve insulin sensitivity, potentially causing excessive blood glucose reduction when combined
Linking gut redox to human microbiome